Preventative therapies for respiratory Syncytial virus (RSV) in children: Where are we now?

Marie-Hélène Bourassa; Larry C Lands

doi:10.1016/j.prrv.2023.08.005

Preventative therapies for respiratory Syncytial virus (RSV) in children: Where are we now?

Paediatr Respir Rev. 2024 Mar:49:24-27. doi: 10.1016/j.prrv.2023.08.005. Epub 2023 Aug 29.

Authors

Marie-Hélène Bourassa¹, Larry C Lands²

Affiliations

¹ Pediatric Respiratory Medicine, Montreal Children's Hospital-McGill University Health Centre, Montreal, Quebec, Canada. Electronic address: [email protected].
² Pediatric Respiratory Medicine, Montreal Children's Hospital-McGill University Health Centre, Montreal, Quebec, Canada. Electronic address: [email protected].

PMID: 37704463
DOI: 10.1016/j.prrv.2023.08.005

Abstract

Respiratory Syncytial Virus (RSV) is a leading cause of hospitalization in young children and represents a substantial health-care burden around the world. Advances in research have helped identify the prefusion F protein as the key target component in RSV immunization. In this article, we review the previous, current, and ongoing research efforts for immunization against RSV in children. We present the different types of immunization which include monoclonal antibodies, maternal immunization and vaccines while addressing the challenges of preventing RSV infections in the pediatric population.

Keywords: Clinical trials; Monoclonal antibodies; Respiratory syncytial virus; Vaccines.

Publication types

Review

MeSH terms

Antibodies, Neutralizing
Antibodies, Viral
Child
Child, Preschool
Humans
Respiratory Syncytial Virus Infections* / prevention & control
Respiratory Syncytial Virus Vaccines* / therapeutic use
Respiratory Syncytial Virus, Human*

Substances

Antibodies, Neutralizing
Antibodies, Viral
Respiratory Syncytial Virus Vaccines